Phase 2Completed
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure (GENETIC-AF)
GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure
- Sponsor
- ARCA Biopharma, Inc. (Industry)
- Enrollment
- 267 enrolled
- Conditions
- Current or Recent History of Atrial Fibrillation
- Interventions
- bucindolol hydrochloride; metoprolol succinate; Placebo oral capsule
- Ages
- adults, older adults
- Registry
- NCT01970501
Full record on ClinicalTrials.gov
From the registry
This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
Primary outcomes
- Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24].
History
Last registry update
Results first posted
Primary completion
Started
Registered